AKIN GUMP STRAUSS HAUER & FELD

Lobbying for AMGEN USA, INC. · Biotechnology healthcare products.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Jul 21, 2025

Lobbying activity 2

Taxation/Internal Revenue Code

Analysis and advice on international tax issues.

Health Issues

Issues related to Most Favored Nation drug pricing.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.